AU2010291933B2 - Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury - Google Patents

Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury Download PDF

Info

Publication number
AU2010291933B2
AU2010291933B2 AU2010291933A AU2010291933A AU2010291933B2 AU 2010291933 B2 AU2010291933 B2 AU 2010291933B2 AU 2010291933 A AU2010291933 A AU 2010291933A AU 2010291933 A AU2010291933 A AU 2010291933A AU 2010291933 B2 AU2010291933 B2 AU 2010291933B2
Authority
AU
Australia
Prior art keywords
biomarker
injury
gfap
biomarkers
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2010291933A
Other languages
English (en)
Other versions
AU2010291933A1 (en
Inventor
Ronald L. Hayes
Ming Cheng Liu
Kevin Ka-Wang Wang
Zhiqun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Banyan Biomarkers Inc
Original Assignee
Banyan Biomarkers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43733138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010291933(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyan Biomarkers Inc filed Critical Banyan Biomarkers Inc
Publication of AU2010291933A1 publication Critical patent/AU2010291933A1/en
Application granted granted Critical
Publication of AU2010291933B2 publication Critical patent/AU2010291933B2/en
Priority to AU2016269481A priority Critical patent/AU2016269481B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2010291933A 2009-09-14 2010-09-14 Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury Expired - Fee Related AU2010291933B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016269481A AU2016269481B2 (en) 2009-09-14 2016-12-07 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24212309P 2009-09-14 2009-09-14
US61/242,123 2009-09-14
US35450410P 2010-06-14 2010-06-14
US61/354,504 2010-06-14
US35577910P 2010-06-17 2010-06-17
US61/355,779 2010-06-17
US38015810P 2010-09-03 2010-09-03
US61/380,158 2010-09-03
PCT/US2010/048789 WO2011032155A2 (en) 2009-09-14 2010-09-14 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016269481A Division AU2016269481B2 (en) 2009-09-14 2016-12-07 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Publications (2)

Publication Number Publication Date
AU2010291933A1 AU2010291933A1 (en) 2012-05-10
AU2010291933B2 true AU2010291933B2 (en) 2016-09-08

Family

ID=43733138

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2010291933A Expired - Fee Related AU2010291933B2 (en) 2009-09-14 2010-09-14 Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
AU2016269481A Ceased AU2016269481B2 (en) 2009-09-14 2016-12-07 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016269481A Ceased AU2016269481B2 (en) 2009-09-14 2016-12-07 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Country Status (8)

Country Link
US (3) US20130022982A1 (cg-RX-API-DMAC7.html)
EP (1) EP2478360B1 (cg-RX-API-DMAC7.html)
JP (3) JP5909447B2 (cg-RX-API-DMAC7.html)
AU (2) AU2010291933B2 (cg-RX-API-DMAC7.html)
CA (1) CA2774173A1 (cg-RX-API-DMAC7.html)
ES (1) ES2687469T3 (cg-RX-API-DMAC7.html)
HU (1) HUE040281T2 (cg-RX-API-DMAC7.html)
WO (1) WO2011032155A2 (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
DK2324360T3 (en) 2008-08-11 2018-05-14 Banyan Biomarkers Inc BIOMARKET DETECTION METHOD AND ASSAY OF NEUROLOGICAL CONDITION
US20170315136A9 (en) * 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
JP5875514B2 (ja) * 2009-06-19 2016-03-02 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
JP5909447B2 (ja) 2009-09-14 2016-04-26 バンヤン・バイオマーカーズ・インコーポレーテッド ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
WO2012045324A1 (en) * 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
JP6071886B2 (ja) 2010-10-14 2017-02-01 ザ・ジョンズ・ホプキンス・ユニバーシティ 脳損傷のバイオマーカー
DE102011011280A1 (de) * 2011-02-15 2012-08-16 Euroimmun Medizinische Labordiagnostika Ag Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antikörpern
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
US20140206777A1 (en) * 2011-08-16 2014-07-24 Rosetta Genomics Ltd. Methods and compositions for diagnosis of alzheimer's disease
HK1206425A1 (en) * 2012-03-13 2016-01-08 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2013173596A1 (en) * 2012-05-16 2013-11-21 Trustees Of Boston University Chronic traumatic encephalopathy in blast-exposed individuals
KR20200013072A (ko) * 2012-07-03 2020-02-05 워싱턴 유니버시티 Tau에 대한 항체
US20140073524A1 (en) * 2012-09-07 2014-03-13 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (ptsd)
US9856532B2 (en) * 2012-09-07 2018-01-02 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (PTSD)
EP3757226A3 (en) 2013-07-17 2021-05-05 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
GB201319761D0 (en) * 2013-11-08 2013-12-25 Nordic Bioscience As Biomarkers of disease progression
CN103656685B (zh) * 2014-01-10 2016-01-13 厦门大学 microRNA-219在制备抗癫痫药物中的应用
WO2015134551A1 (en) * 2014-03-03 2015-09-11 Banyan Biomarkers, Inc. Micro rna markers for diagnosis of a neurological condition
US9605315B2 (en) 2014-03-26 2017-03-28 The University Of Montana Detection of traumatic brain injury
EP3129780A4 (en) * 2014-04-07 2017-12-13 Iron Horse Diagnostics Inc. Traumatic brain injury and neurodegenerative biomarkers, methods, and systems
CN106605146B (zh) * 2014-04-08 2020-07-28 佛罗里达大学研究基金会有限公司 用于中枢神经系统的急性、亚急性和慢性创伤性损伤的蛋白质标志物
WO2015160391A1 (en) * 2014-04-15 2015-10-22 The Government Of The United States, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research Diagnosis and treatment of tauopathy and chronic traumatic encephalopathy
WO2015196191A1 (en) * 2014-06-20 2015-12-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Microrna biomarkers for traumatic brain injury and methods of use thereof
WO2016049429A1 (en) * 2014-09-26 2016-03-31 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Microrna biomarkers for posttraumatic stress disorder and methods of use thereof
CN107003317B (zh) * 2014-10-06 2019-04-19 日内瓦大学 生物标记及其在脑损伤中的应用
CN107533048A (zh) * 2015-02-05 2018-01-02 美国免疫阵列公司 用于诊断脑损伤或神经退行性变的方法和组合物
WO2016205730A1 (en) * 2015-06-18 2016-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Citrullinated proteins and their breakdown products as tbi biomarkers
EP3329005B1 (en) * 2015-07-29 2020-05-13 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Microrna biomarkers for traumatic brain injury and methods of use thereof
WO2017044650A1 (en) * 2015-09-08 2017-03-16 The Translational Genomics Research Institute Biomarkers and methods of diagnosing and prognosing mild traumatic brain injuries
CA3042630A1 (en) * 2015-11-18 2017-05-26 Dignity Health Methods of diagnosing epilepsy
GB201603967D0 (en) * 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
WO2017187696A1 (ja) * 2016-04-28 2017-11-02 一般財団法人生産技術研究奨励会 神経細胞を培養する装置、神経細胞を培養する方法、培養された神経細胞、軸索束内のプロテインを解析及び同定する方法並びに神経細胞の使用方法
EP3452832A4 (en) * 2016-05-06 2020-04-22 Duke University METHODS AND KITS FOR DIAGNOSIS AND TREATMENT OF DISEASES OR INJURIES OF THE NERVOUS SYSTEM
WO2018048884A1 (en) 2016-09-09 2018-03-15 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating autoimmune gfap astrocytopathy
IT201600093825A1 (it) * 2016-09-19 2018-03-19 Fondazione St Italiano Tecnologia Composizione farmaceutica di miRNA e suoi usi terapeutici.
EP3532496A1 (en) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
ES2975228T3 (es) * 2016-11-23 2024-07-04 Randox Laboratories Ltd Derivados de GFAP para el diagnóstico de accidente cerebrovascular
AU2018219790B2 (en) * 2017-02-07 2024-10-10 Bioregency, Inc. S100β and isoforms for detection of neurological conditions
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
WO2018190365A1 (ja) * 2017-04-12 2018-10-18 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
US10877048B2 (en) 2017-04-15 2020-12-29 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
CA3053410A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
CA3078725A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
BR112019025387A2 (pt) 2017-05-30 2020-07-07 Abbott Laboratories métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces
CN110998321A (zh) * 2017-06-02 2020-04-10 约翰霍普金斯大学 帕金森氏症患者脑脊液中par的检测方法
KR20200026834A (ko) 2017-06-02 2020-03-11 더 존스 홉킨스 유니버시티 파킨슨병에 걸린 환자의 csf 중 par의 검출
DK3642365T3 (da) * 2017-06-19 2021-10-18 St Johns Univ Cirkulerende serum-mikro-rna-biomarkører og fremgangsmåder til bestemmelse af progressionsraten af parkinsons sygdom
CA3068041C (en) 2017-07-03 2024-06-25 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
EP3700556A2 (en) 2017-10-25 2020-09-02 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
JP6942036B2 (ja) * 2017-11-30 2021-09-29 藤倉化成株式会社 脳梗塞の発症リスクを高感度に検出する体液抗体バイオマーカー
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
EP3732489B1 (en) 2017-12-29 2025-10-22 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
KR102026675B1 (ko) * 2018-02-12 2019-09-30 강원대학교산학협력단 miR-135a-5p 및 p62에 의한 알레르기 반응 조절 메커니즘 및 이의 이용
CA3093455A1 (en) * 2018-03-08 2019-09-12 Meso Scale Technologies, Llc. Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury
JP6499342B2 (ja) * 2018-03-19 2019-04-10 隆樹 日和佐 脳梗塞の診断マーカー
US20210230255A1 (en) * 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US20210292840A1 (en) * 2018-07-25 2021-09-23 Srnalytics, Inc. Small rna predictors for alzheimer's disease
CN110824156B (zh) * 2018-08-14 2023-08-11 欧蒙医学诊断（中国）有限公司 神经自身免疫疾病的诊断
WO2020037311A1 (en) * 2018-08-17 2020-02-20 University Of Florida Research Foundation, Inc. Protein and peptide biomarkers for traumatic injury to the central nervous system
WO2020081641A1 (en) * 2018-10-17 2020-04-23 Ochsner Health System Plasma and cerebrospinal fluid mirna biomarkers in intracerebral and subarachnoid hemorrhage
CN109266739A (zh) * 2018-11-29 2019-01-25 成都仕康美生物科技有限公司 一种检测脑损伤的miRNA标志物、试剂盒、应用
CN113383090A (zh) * 2018-12-04 2021-09-10 拉筹伯大学 诊断疾病状态的方法
BR112021014794A2 (pt) 2019-02-08 2021-10-05 Ac Immune S.A. Método de administração segura de vacina de peptídeo de tau fosforilada
PL3924518T3 (pl) * 2019-02-14 2025-08-11 Marker Diagnostics Uk Limited Obecne w ślinie biomarkery urazu mózgu
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
US11644463B2 (en) * 2019-08-30 2023-05-09 Euroimmun Medizinische Labordiagnostika Ag Detection of an autoantibody
US20230250480A1 (en) * 2020-07-09 2023-08-10 University Of Florida Research Foundation, Incorporated Biofluid-based protein and mirna biomarkers for neonatal hypoxic-ischemic encephalopathy
EP4200331A4 (en) * 2020-08-24 2024-09-18 Marabio Systems, Inc. METHODS TO REDUCE AUTOANTIBODIES IN THE MOTHER
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트
CN113238045B (zh) * 2021-04-27 2021-12-28 南方医科大学南方医院 Crmp2及抗crmp2抗体的应用
KR102759445B1 (ko) * 2021-11-16 2025-01-24 한국한의학연구원 치료에 따른 보행 장애 개선 판별용 바이오마커 및 이의 용도
TWI853766B (zh) * 2022-12-22 2024-08-21 國立臺灣大學 用於心跳停止病患頭部電腦斷層之灰白質比率自動計算方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
AU663053B2 (en) 1990-06-11 1995-09-28 Gilead Sciences, Inc. Nucleic acid ligands
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
US5731410A (en) 1994-11-28 1998-03-24 University Of Utah Research Foundation Peptide for blocking autoantibody-evoked activation of glutamate receptor type 3 (GLUR3)
WO2000014546A1 (en) 1998-09-08 2000-03-16 Innogenetics N.V. Tau as a marker for early cns damage
US20020002270A1 (en) 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
US6589746B1 (en) * 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20020172676A1 (en) * 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
ATE445160T1 (de) 2001-08-20 2009-10-15 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
AU2002329570A1 (en) * 2001-10-12 2003-01-30 Pfizer Products Inc. Method of monitoring neuroprotective treatment
EP1551450A4 (en) 2002-06-12 2005-11-23 Cleveland Clinic Foundation MARKER FOR THE PERMEABILITY OF THE BLOOD BARRIER AND METHOD FOR THEIR USE
JP2005538380A (ja) 2002-09-11 2005-12-15 ユニヴァーシティ オヴ フロリダ 神経細胞損傷の分析
CA2511501A1 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
DK2357477T3 (en) 2003-09-20 2018-02-05 Electrophoretics Ltd Diagnostic approach for brain injury-related disorders based on detection of NDKA
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
CA2578670C (en) 2004-04-15 2017-03-07 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US7456027B2 (en) * 2004-04-15 2008-11-25 University Of Florida Research Foundation, Inc. Proteolytic biomarkers for traumatic injury to the nervous system
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
EP1949103A2 (en) 2005-10-20 2008-07-30 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US8563291B2 (en) 2006-02-15 2013-10-22 Mie University Method of constructing recombinant proteoliposome for diagnostic use
WO2007136617A2 (en) * 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
WO2007140188A2 (en) 2006-05-26 2007-12-06 Biosite Incorporated Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
EP3115785A3 (en) * 2008-02-04 2017-02-22 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
DK2324360T3 (en) 2008-08-11 2018-05-14 Banyan Biomarkers Inc BIOMARKET DETECTION METHOD AND ASSAY OF NEUROLOGICAL CONDITION
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
WO2010059242A2 (en) 2008-11-21 2010-05-27 The Johns Hopkins University Neurodegenerative disease diagnostic compositions and methods of use
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
JP5875514B2 (ja) 2009-06-19 2016-03-02 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
WO2011011334A2 (en) 2009-07-18 2011-01-27 Banyan Biomarkers, Inc. SYNERGISTIC BIOMARKER ASSAY OF NEUROLGICAL CONDITION USING S-100β
JP5909447B2 (ja) 2009-09-14 2016-04-26 バンヤン・バイオマーカーズ・インコーポレーテッド ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
EP2553466A4 (en) * 2010-04-01 2013-10-16 Banyan Biomarkers Inc MARKERS AND ASSAYS FOR DETECTING NEUROTOXICITY
WO2011160096A2 (en) 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
CN103959067B (zh) 2011-09-14 2018-04-24 促进军事医学的亨利·M·杰克逊基金会公司 用于检测和监测用于创伤后应激障碍（ptsd）的诊断生物标志物以及用于区分自杀式与非自杀式障碍的试剂盒
US20140024053A1 (en) 2012-07-20 2014-01-23 Banyan Biomarkers, Inc. Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
US20140275294A1 (en) 2013-03-15 2014-09-18 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of liver injury
US20150141528A1 (en) 2013-05-31 2015-05-21 Banyan Biomarkers, Inc. Neural specific s100b for biomarker assays and devices for detection of a neurological condition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEKHONIN, V. P. et al., Immunologija, 1996, vol.17, pages 67-69 *
EL-FAWAL, H. A. N., et al., NeuroToxicology, 2008, vol. 29, pages 109-115 *

Also Published As

Publication number Publication date
CA2774173A1 (en) 2011-03-17
JP2016105097A (ja) 2016-06-09
ES2687469T3 (es) 2018-10-25
JP6469760B2 (ja) 2019-02-13
US20170242041A1 (en) 2017-08-24
HUE040281T2 (hu) 2019-03-28
AU2016269481B2 (en) 2018-08-30
WO2011032155A3 (en) 2011-10-06
JP5909447B2 (ja) 2016-04-26
JP2017181518A (ja) 2017-10-05
EP2478360B1 (en) 2018-06-27
EP2478360A4 (en) 2013-04-03
EP2478360A2 (en) 2012-07-25
US20130022982A1 (en) 2013-01-24
AU2016269481A1 (en) 2016-12-22
US20190064188A1 (en) 2019-02-28
JP2013504331A (ja) 2013-02-07
WO2011032155A2 (en) 2011-03-17
US10041959B2 (en) 2018-08-07
AU2010291933A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
AU2010291933B2 (en) Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
AU2011235892B2 (en) Markers and assays for detection of neurotoxicity
EP3336551B1 (en) Biomarker detection process and assay of neurological condition
AU2010262952B2 (en) Biomarker assay of neurological condition
US20150268252A1 (en) Biomarker assay of neurological condition
US20110082203A1 (en) Process to diagnose or treat brain injury
US20170176460A1 (en) Neural specific s100-beta for biomarker assays and devices for detection of a neurological condition
WO2011160096A2 (en) Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
JP6338872B2 (ja) 視神経障害発症リスクの判定方法
AU2015203660A1 (en) Process to diagnose or treat brain injury

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee